JBS Stock Analysis: JBS | NYSE
Packaged Foods | NYSE, USA | Market Cap: 14.725m USD | 12M Return: -11% | NL0015002J37 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 75.9M
EPS Trend: 92.9%
Qual. Beats: 0
Rev. Trend: 73.2%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
JBS N.V. is a global processor of animal proteins, with operations spanning beef, pork, lamb, and poultry, complemented by prepared foods and a diversified portfolio of related businesses such as leather, collagen, hygiene products, metal packaging, and biodiesel. The company sells under numerous consumer-facing brands, including Seara, Pilgrims, Moy Park, Friboi, and Swift. Founded in 1953 and headquartered in Amstelveen, the Netherlands, JBS operates a vertically integrated model that extends from livestock production to branded packaged foods, allowing it to capture value across the protein supply chain. The meat processing industry is generally characterized by stable consumer demand, benefiting from its position in the defensive Consumer Staples sector.
- US beef margins expand as cattle herd shrinks
- Seara branded prepared foods drive higher margin growth
- Pilgrims Pride earnings recover on lower feed costs
| Net Income: 6.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.36 > 1.0 |
| NWC/Revenue: -11.16% < 20% (prev 6.63%; Δ -17.80% < -1%) |
| CFO/TA 0.29 > 3% & CFO 13.1b > Net Income 6.41b |
| Net Debt (22.8b) to EBITDA (27.3b): 0.83 < 3 |
| Current Ratio: 0.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.02b) vs 12m ago -53.97% < -2% |
| Gross Margin: 11.86% > 18% (prev 14.55%; Δ -2.69% > 0.5%) |
| Asset Turnover: 279.0% > 50% (prev 201.8%; Δ 77.23% > 0%) |
| Interest Coverage Ratio: 2.47 > 6 (EBIT TTM 14.7b / Interest Expense TTM 5.95b) |
| A: -0.93 (Total Current Assets 17.8b - Total Current Liabilities 60.4b) / Total Assets 45.8b |
| B: 0.00 (Retained Earnings 118.5m / Total Assets 45.8b) |
| C: 0.11 (EBIT TTM 14.7b / Avg Total Assets 137b) |
| D: 0.22 (Book Value of Equity 8.22b / Total Liabilities 36.8b) |
| Altman-Z'' = -5.14 = D |
| DSRI: 0.18 (Receivables 3.56b/23.5b, Revenue 382b/460b) |
| GMI: 1.23 (GM 14.55% / 11.86%) |
| AQI: 0.97 (AQ_t 0.26 / AQ_t-1 0.27) |
| SGI: 0.83 (Revenue 382b / 460b) |
| TATA: -0.15 (NI 6.41b - CFO 13.1b) / TA 45.8b) |
| Beneish M = -3.65 (Cap -4..+1) = AAA |
As of August 28, 2026, the stock is trading at USD 13.62 with a total of 5,727,996 shares traded. Over the past week, the price has changed by +0.52%, over one month by +0.52%, over three months by +3.03% and over the past year by -11.00%.
Current recommended Stop Loss: 12.90 (which is 5.3% or 1.6 ATR below the current price).
JBS has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy JBS.
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18.2 | 33.7% |
P/E Trailing = 13.0952
P/E Forward = 3.8715
P/S = 0.4961
P/B = 5.6194
Revenue TTM = 382b USD
EBIT TTM = 14.7b USD
EBITDA TTM = 27.3b USD
Long Term Debt = 20.3b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.70b USD (from shortTermDebt, last quarter)
Debt = 26.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.78b
Net Debt = 22.8b USD (calculated: Debt 26.2b - CCE 3.47b)
Enterprise Value = 37.5b USD (14.7b + Debt 26.2b - CCE 3.47b)
Interest Coverage Ratio = 2.47 (Ebit TTM 14.7b / Interest Expense TTM 5.95b)
EV/FCF = 17.52x (Enterprise Value 37.5b / FCF TTM 2.14b)
FCF Yield = 5.71% (FCF TTM 2.14b / Enterprise Value 37.5b)
FCF Margin = 0.56% (FCF TTM 2.14b / Revenue TTM 382b)
Net Margin = 1.68% (Net Income TTM 6.41b / Revenue TTM 382b)
Gross Margin = 11.86% ((Revenue TTM 382b - Cost of Revenue TTM 337b) / Revenue TTM)
Gross Margin QoQ = 10.83% (prev 10.42%)
Tobins Q-Ratio = 0.82 (Enterprise Value 37.5b / Total Assets 45.8b)
Interest Expense / Debt = 22.69% (Interest Expense 5.95b / Debt 26.2b)
Taxrate = 10.32% (801.5m / 7.77b)
NOPAT = 13.2b (EBIT 14.7b * (1 - 10.32%))
Current Ratio = 0.29 (Total Current Assets 17.8b / Total Current Liabilities 60.4b)
Debt / Equity = 3.19 (Debt 26.2b / totalStockholderEquity, last quarter 8.22b)
Debt / EBITDA = 0.83 (Net Debt 22.8b / EBITDA 27.3b)
Debt / FCF = 10.64 (Net Debt 22.8b / FCF TTM 2.14b)
Total Stockholder Equity = 36.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.68% (Net Income 6.41b / Total Assets 45.8b)
RoE = 17.67% (Net Income TTM 6.41b / Total Stockholder Equity 36.3b)
RoCE = 25.99% (EBIT 14.7b / Capital Employed (Equity 36.3b + L.T.Debt 20.3b))
RoIC = 40.55% (NOPAT 13.2b / Invested Capital 32.5b)
WACC = 14.72% (E(14.7b)/V(41.0b) * Re(4.71%) + D(26.2b)/V(41.0b) * Rd(22.69%) * (1-Tc(0.10)))
Discount Rate = 4.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.70 | Cagr: -29.16%
[DCF] Terminal Value 53.24% ; FCFF base≈4.30b ; Y1≈3.77b ; Y5≈3.04b
[DCF] Fair Price = 1.77 (EV 24.1b - Net Debt 22.8b = Equity 1.38b / Shares 776.1m; r=14.72% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 92.87 | EPS CAGR: 372.8% | SUE: -0.45 | # QB: 0
Revenue Correlation: 73.18 | Revenue CAGR: 9.65% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.12 | Chg30d=-2.85% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=4.86 | Chg30d=-30.16% | Revisions=-17% | GrowthEPS=-57.3% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=7.38 | Chg30d=-9.72% | Revisions=-50% | GrowthEPS=+51.9% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: -50% (up=1, down=6)